版本:
中国

BRIEF-Aveo Oncology announces phase 1/2 tinivo trial

June 8 Aveo Pharmaceuticals Inc:

* Aveo Oncology announces phase 1/2 tinivo trial of tivozanib and opdivo® (nivolumab) in RCC advances to phase 2

* Aveo Pharmaceuticals - "Registration strategy for single agent tivozanib reaches key inflection points, with European regulatory decision expected in near-term"

* Aveo - if registration strategy for single agent tivozanib reaches key inflection points, readout of us registration-directed tivo-3 study expected in Q1 of 2018 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐